# US 2015/0306011 A1 · Methods for using soy peptides to inhibit h3 acetylation, reduce expression of hmg-coa reductase and increase ldl receptor and sp1 expression in a mammal

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0306011 A1
- Document ID: US20150306011A1
- Status: Published application
- Kind: A1
- Application number: 14/261,080
- Filed: 2014-04-24
- Published: 2015-10-29
- Earliest claimed: 2014-04-24
- Inventors: ALFREDO FLORES GALVEZ
- Web page: https://patentgrep.com/patent/US20150306011A1

## CPC

- A61K 8/645: {Proteins of vegetable origin; Derivatives or degradation products thereof}
- A61Q 19/08: Anti-ageing preparations
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Controlled studies demonstrate that methods using soy related peptides inhibit H3 acetylation, reduce expression of HMG-CoA reductase and increase LDL receptor and Sp1 expression in mammals. The present disclosure is generally directed to using lunasin peptides and/or lunasin peptide derivatives to 1) inhibit H3 acetylation, 2) reduce expression of HMG-CoA reductase, 3) increase LDL receptor expression or 4) increase Sp1 expression in a mammal. In at least one exemplary embodiment of the present disclosure, an effective amount of lunasin peptides or lunasin peptide derivatives and one or more enzyme inhibitors is provided to a mammal to 1) inhibit H3 acetylation, 2) reduce expression of HMG-CoA reductase, 3) increase LDL receptor expression or 4) increase Sp1 expression in a mammal. Additionally, lunasin will protect against, prevent, or reduce: 1) the expression of Matrix metalloproteinase (MMP-1), 2) collagen breakdown, 3) photoaging and 4) the formation of skin wrinkles.

## Claims

### Claim 1

A method for protecting against photoaging of skin in an individual, comprising: (a) providing: (i) an individual desiring to prevent photoaging of skin and, (ii) a composition comprising a compound selected from the group consisting of the peptide of SEQ ID NO 2 and a functionally equivalent variant, fragment or analogue of said peptide; and (b) administering said composition to said subject to protect against photoaging.

### Claim 2 (depends on 1)

The method of claim 1, wherein said compound is obtained from soybean, wheat or barley.

### Claim 3 (depends on 1)

The method of claim 1, wherein said compound is obtained by producing, extracting and purifying said compound using recombinant DNA techniques.

### Claim 4 (depends on 1)

The method of claim 1, wherein said compound is obtained by synthetic polypeptide production.

### Claim 5 (depends on 1)

The method of claim 1, wherein said individual is a human.

### Claim 6 (depends on 1)

The method of claim 1 wherein administering comprises topical administration of the composition.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition is in the form of a semi-solid formulation, liquid, gel, suspension, or aerosol spray.

### Claim 8 (depends on 1)

The method of claim 1, wherein said composition further comprises chymotrypsin inhibitor.

### Claim 9 (depends on 1)

The method of claim 1, wherein said compound is administered to said individual at between 5 μg/ml and 50 μg/ml.

### Claim 10

A method for protecting against collagen breakdown in the skin of an individual, comprising: (a) providing: (i) an individual desiring to prevent collagen breakdown in the skin and, (ii) a composition comprising a compound selected from the group consisting of the peptide of SEQ ID NO 2 and a functionally equivalent variant, fragment or analogue of said peptide; and (b) administering said composition to said subject to protect against collagen breakdown.

### Claim 11 (depends on 10)

The method of claim 10, wherein said compound is obtained from soybean, wheat or barley.

### Claim 12 (depends on 10)

The method of claim 10, wherein said compound is obtained by producing, extracting and purifying said compound using recombinant DNA techniques.

### Claim 13 (depends on 10)

The method of claim 10, wherein said compound is obtained by synthetic polypeptide production.

### Claim 14 (depends on 10)

The method of claim 10, wherein said individual is a human.

### Claim 15 (depends on 10)

The method of claim 10 wherein administering comprises topical administration of the composition.

### Claim 16 (depends on 10)

The method of claim 10, wherein the composition is in the form of a semi-solid formulation, liquid, gel, suspension, or aerosol spray.

### Claim 17 (depends on 10)

The method of claim 10, wherein said composition further comprises chymotrypsin inhibitor.

### Claim 18 (depends on 10)

The method of claim 10, wherein said compound is administered to said individual at between 5 μg/ml and 50 μg/ml.

### Claim 19

A method for protecting against wrinkling of the skin in an individual, comprising: (a) providing: (i) an individual desiring to prevent wrinkling of skin and, (ii) a composition comprising a compound selected from the group consisting of the peptide of SEQ ID NO 2 and a functionally equivalent variant, fragment or analogue of said peptide; and (b) administering said composition to said subject to protect against wrinkling of the skin.

### Claim 20 (depends on 19)

The method of claim 19, wherein said compound is obtained from soybean, wheat or barley.

### Claim 21 (depends on 19)

The method of claim 19, wherein said compound is obtained by producing, extracting and purifying said compound using recombinant DNA techniques.

### Claim 22 (depends on 19)

The method of claim 19, wherein said compound is obtained by synthetic polypeptide production.

### Claim 23 (depends on 19)

The method of claim 19, wherein said individual is a human.

### Claim 24 (depends on 19)

The method of claim 19 wherein administering comprises topical administration of the composition.

### Claim 25 (depends on 19)

The method of claim 19, wherein the composition is in the form of a semi-solid formulation, liquid, gel, suspension, or aerosol spray.

### Claim 26 (depends on 19)

The method of claim 19, wherein said composition further comprises chymotrypsin inhibitor.

### Claim 27 (depends on 19)

The method of claim 19, wherein said compound is administered to said individual at between 5 μg/ml and 50 μg/ml.
